Galderma, the pure-play dermatology category leader with operations in nearly 90 countries, will present ten scientific posters highlighting the latest advances across its injectable aesthetics portfolio at the International Master Course on Aging Science (IMCAS) 2026 World Congress, to be held in Paris, France, from January 29 to 31, 2026.

In addition to scientific presentations, Galderma will demonstrate its commitment to medical education through two symposia, a live anatomy workshop, multiple masterclasses, meet-the-expert sessions, and an interactive booth focused on the science behind its innovations.

According to Bill Andriopoulos, Ph.D., Head of Global Medical Affairs at Galderma, the data presented at IMCAS reflects the breadth and versatility of the company’s injectable aesthetics portfolio across the face and body. He added that through its Galderma Aesthetic Injector Network (GAIN), delivered in collaboration with leading global experts, the company continues to equip practitioners with tools to deliver personalized and holistic treatment approaches.

Responding to growing patient interest in balanced facial and body aesthetics, Galderma recently received EU MDR certification for Sculptra, the first proven regenerative biostimulator, expanding its clinical use to body indications. At IMCAS, expert guidance developed by 13 international specialists will be presented, covering four MDR-approved indications for Sculptra: the gluteal area, posterior thighs, décolletage, and upper arms. The guidance highlights complementary use with Restylane Skinboosters for comprehensive body rejuvenation and outlines recommended injection volumes to improve skin firmness and reduce the appearance of cellulite.

Additional posters will present evidence supporting Sculptra’s regenerative mechanism, including fibroblast activation that stimulates collagen, elastin, and extracellular matrix regeneration, as well as adipogenesis. These biological effects translate clinically into long-term improvements in skin thickness, elasticity, and volume. Another study will compare the reconstitution process of Sculptra with other poly-L-lactic acid biostimulators, showing a strong healthcare professional preference for Sculptra based on ease of preparation and speed of administration.

Galderma will also present data across its Restylane hyaluronic acid (HA) portfolio, reinforcing its versatility for facial and décolletage treatments. Findings include studies on chin shaping, jawline definition, wrinkle correction in the décolletage, temple hollowing, and skin quality improvement, with results demonstrating safety, effectiveness, and high patient satisfaction across indications and time points extending up to 18 months.

New analyses from the RELAX and EXPRESSION trials evaluating Relfydess, the first ready-to-use liquid neuromodulator developed with PEARL Technology, will also be shared. Results confirm onset of action as early as Day 1 for moderate-to-severe frown lines and crow’s feet, with sustained improvements lasting up to six months. Expert consensus recommendations will provide practical guidance for real-world clinical use.

Further reinforcing its holistic approach, Galderma will present findings from a global survey of more than 4,300 women linking menopause to skin changes such as wrinkles, dryness, loss of firmness, and dullness, and highlighting the potential role of aesthetic treatments. A dedicated symposium titled “Menopause in the Mirror: Challenges, Science and Aesthetic Solutions” will address these findings. A second symposium will focus on emerging regenerative injectable solutions for face, body, and skin health.

Through its scientific presentations and extensive educational programming at IMCAS 2026, Galderma aims to advance evidence-based aesthetics and support healthcare professionals in delivering personalized, regenerative, and natural-looking outcomes for patients.